Anecortave (rINN) (IPA: ) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although based on a steroid nucleus, it possesses little glucocorticoid activity. It is marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane.

External links

Angiogenesis inhibitors | Steroids